Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of thalassemia
3.2.1.2 Technological advancements
3.2.1.3 Rise in awareness regarding thalassemia treatment
3.2.1.4 Surge in R&D investments
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory scenario
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.7 New emerging therapies
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Blood transfusions
5.3 Iron chelation therapy
5.4 Folic acid supplements
5.5 Other treatment types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Alpha thalassemia
6.3 Beta thalassemia
Chapter 7 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Super specialty clinics
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Bluebird Bio
9.2 Bristol-Myers Squibb Company
9.3 CHIESI Farmaceutici S.p.A.
9.4 Kiadis Pharma
9.5 Merck & Co., Inc.
9.6 Novartis AG
9.7 Pfizer, Inc.
9.8 SG Phrma Pvt. Lmt.
